Proposed Investment in Evgen Pharma plc
3 February 2021
Intuitive Investments Group plc
Proposed Investment in Evgen Pharma plc
Intuitive Investments Group plc (AIM: IIG) ("IIG"), a closed-end investment company focussed on the life sciences sector, announces an investment of £175,000 to acquire 2,187,500 million ordinary shares of Evgen Pharma plc (AIM:EVG) ("Evgen") at a price of 8 pence per share (the "Investment"). The Investment is part of the fundraising announced by Evgen on 2 February 2021. The Investment is conditional upon, amongst other things, the resolutions being passed at Evgen's forthcoming general meeting on 3 March 2021.
Evgen is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases.
The Investment in Evgen is the Company's fourth investment following its IPO in mid-December 2020.
David Evans, Chairman of IIG, has a pre-existing interest of 145,000 ordinary shares in Evgen and accordingly did not participate in the Company's decision to approve the Investment.
For further information, please contact:
|
Intuitive Investments Group plc |
|
|
David Evans |
Via Walbrook PR |
|
|
|
|
Strand Hanson Limited - Nominated Adviser |
+44 (0) 20 7409 3494 |
|
James Harris / James Dance / James Bellman |
|
|
|
|
|
Turner Pope Investments (TPI) Ltd - Broker |
+44 (0) 20 3657 0050 |
|
Andrew Thacker / Zoe Alexander |
|
|
|
|
|
Walbrook PR Limited - Media & Investor Relations |
+44 (0)20 7933 8780 or intuitive@walbrookpr.com |
|
Paul McManus |
+44 (0) 7980 541 893 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 16 hours ago Cerillion
- 18 hours ago Associated British Foods
- 18 hours ago B&M European Value Retail S.A. (DI)
- 18 hours ago B&M European Value Retail S.A. (DI)
- 18 hours ago Haleon